Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 2251 - 2275 of 15114 in total

Panitumumab

Panitumumab (ABX-EGF) is a recombinant human IgG2 monoclonal antibody that binds specifically to the human epidermal growth factor receptor (EGFR). This drug is an antineoplastic agent. Panitumumab was granted FDA approval on 27 September 2006.
Approved
Investigational
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Daratumumab

Daratumumab is an immunoglobulin G1 kappa monoclonal antibody developed by Janssen and Genmab. It was first described in the literature in 2010 as a monoclonal antibody that targets CD38+ multiple myeloma cells; the first of its kind. Daratumumab was granted FDA approval on 16 November 2015. It is approved for...
Approved
Matched Description: … Daratumumab is an immunoglobulin G1 kappa monoclonal antibody developed by Janssen and Genmab. ... [L13290] It is approved for the treatment of multiple myeloma as monotherapy or combination therapy and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Tasonermin

Tasonermin is recombinant soluble form tumor necrosis factor α produced via Escherichia coli cell culture. It was approved for use by the European Medicines Agency in April of 1999 for use as an adjunt to surgery for the subsequent removal of the tumor and in palliative care for irresectable soft...
Approved
Matched Description: … Medicines Agency in April of 1999 for use as an adjunt to surgery for the subsequent removal of the tumor and …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Tisotumab vedotin

Tisotumab vedotin is a tissue factor-directed antibody-drug conjugate (ADC) comprised of an anti-tissue factor (TF) human IgG1-kappa antibody conjugated to monomethyl auristatin E (MMAE), a microtubule-disrupting agent, via a protease-cleavable valine-citrulline linker. Each monoclonal antibody molecule carries an average of four MMAE molecules. Tisotumab vedotin is the first TF-directed ADC...
Approved
Matched Description: … head and neck cancers. ... tumor-associated angiogenesis, progression, and metastasis for tumor survival. ... This is the first and only approved antibody-drug conjugate for this therapeutic indication. …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Danazol

A synthetic steroid with antigonadotropic and anti-estrogenic activities that acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins. It possesses some androgenic properties. Danazol has been used in the treatment of endometriosis and some benign breast disorders.
Approved
Matched Description: … Danazol has been used in the treatment of endometriosis and some benign breast disorders. ... A synthetic steroid with antigonadotropic and anti-estrogenic activities that acts as an anterior pituitary …
Matched Categories: … Antigonadotropins and Similar Agents ... Genito Urinary System and Sex Hormones ... Sex Hormones and Modulators of the Genital System ... Hormones, Hormone Substitutes, and Hormone Antagonists …

Pegcetacoplan

Pegcetacoplan is a complement inhibitor indicated in the treatment of paroxysmal nocturnal hemoglobinuria (PNH).[A235000,L34095] Prior to its FDA approval, patients with PNH were typically treated with the C5 inhibiting monoclonal antibody eculizumab. Patients given eculizumab experienced less hemolysis caused by the membrane attack complex, but were still somewhat susceptible to...
Approved
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …

Saquinavir

Saquinavir is an HIV-1 protease inhibitor used in combination with ritonavir and other antiretrovirals for the treatment of human immunodeficiency virus-1 (HIV-1) infection. In 1995 it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and remains in clinical use today due to a...
Approved
Investigational
Matched Description: … Saquinavir is an HIV-1 protease inhibitor used in combination with [ritonavir] and other antiretrovirals ... it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and ... the co-administration of ritonavir - a potent enzyme inhibitor - that increases the bioavailability and …
Matched Categories: … Metabolic Side Effects of Drugs and Substances …

Moxetumomab pasudotox

CD22 is a lineage-restricted B-cell antigen that is expressed solely in on B-chronic lymphocytic leukemia, hairy cell leukemia, acute lymphocytic leukemiathe and Burkitt's lymphoma. The predecessor of Moxetumab pasudotox (MxP), named BL22, was first created based on the antibody RFB4 which specifically binds to CD22. This antibody was used to...
Approved
Investigational
Matched Description: … the status of Fast Track, Priority Review and Orphan Drug designations. ... expressed solely in on B-chronic lymphocytic leukemia, hairy cell leukemia, acute lymphocytic leukemiathe and ... [A38864] MxP appears as an improved form of BL22 by the mutation of the Fv region and the antibody …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Belantamab mafodotin

Belantamab mafodotin, or GSK2857916, is an afucosylated monoclonal antibody that targets B cell maturation antigen conjugated to the microtubule disrupter monomethyl auristatin-F (MMAF). Belantamab mafodotin was granted FDA accelerated approval on 5 August 2020 for the treatment of multiple myeloma; however, its manufacturer began the process for withdrawal of the...
Approved
Matched Description: … In the meantime, belantamab mafodotin will be available for patients in the Risk Evaluation and Mitigation …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Vasopressin

Vasopressin (arginine-vasopressin or antidiuretic hormone) is a nonapeptide primarily produced in the hypothalamus that exhibits diverse physiological functions related to diuresis, hemodynamic modulation, and behaviour.[A110, A111, A112, A113, A228008] Vasopressin is very similar to oxytocin, differing in the third and eighth amino acids. Despite a wide variety of functions, exogenous...
Approved
Matched Description: … renal fluid reuptake by acting through V1 and V2 cellular receptors. ... [A110, A111, A112, A113, A228008] Vasopressin is very similar to oxytocin, differing in the third and ... hypothalamus that exhibits diverse physiological functions related to diuresis, hemodynamic modulation, and …
Matched Categories: … Vasopressin and Analogues ... Amino Acids, Peptides, and Proteins ... Hormones, Hormone Substitutes, and Hormone Antagonists …

Iron protein succinylate

Approved
Investigational
Matched Categories: … Blood and Blood Forming Organs ... Amino Acids, Peptides, and Proteins …

Anifrolumab

Anifrolumab, or MEDI-546, is a type 1 interferon receptor (IFNAR) inhibiting IgG1κ monoclonal antibody indicated in the treatment of adults with moderate to severe systemic lupus erythematosus.[A237074,L34929] The standard therapy for systemic lupus erythematosus consists of antimalarials like hydroxychloroquine, glucocorticoids like dexamethasone, and disease modifying antirheumatic drugs like methotrexate.[A237079,L34929] Three...
Approved
Investigational
Matched Description: … [A237079,L34929] Three monoclonal antibodies (anifrolumab, [rontalizumab], and [sifalimumab]) that ... erythematosus consists of antimalarials like [hydroxychloroquine], glucocorticoids like [dexamethasone], and ... placebo groups; and patient populations were largely homogenous, which may have increased the odds of …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …

Protein hydrolysate

Approved
Matched Categories: … Amino Acids, Peptides, and Proteins …

Tropicamide

Tropicamide is an alkaloid atropine‐derived anticholinergic drug and a non‐selective antagonist of muscarinic acetylcholine (mACh) receptors. Usually available in ophthalmic formulations, tropicamide is used to cause mydriasis and cycloplegia for eye exams or ocular procedures. It is also used in combination with hydroxyamphetamine for the same indication. Oral tropicamide has...
Approved
Investigational
Matched Description: … Tropicamide is an alkaloid atropine‐derived anticholinergic drug and a non‐selective antagonist of muscarinic ... [A230103] Usually available in ophthalmic formulations, tropicamide is used to cause mydriasis and cycloplegia …
Matched Categories: … Mydriatics and Cycloplegics …

Methazolamide

A carbonic anhydrase inhibitor that is used as a diuretic and in the treatment of glaucoma.
Approved
Matched Description: … A carbonic anhydrase inhibitor that is used as a diuretic and in the treatment of glaucoma. …
Matched Categories: … Antiglaucoma Preparations and Miotics ... Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics …

Spesolimab

Spesolimab is an interleukin-36 (IL-36) receptor antagonist. It is a humanized monoclonal immunoglobulin G1 antibody that was produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology. The biosimilar of the drug, spesolimab-sbzo, was first approved by the FDA in September 2022 to treat generalized pustular psoriasis flares. Spesolimab...
Approved
Investigational
Matched Description: … works by inhibiting the inflammatory signaling pathway of IL-36,[L43090] which is often overexpressed and ... Committee for Medicinal Products for Human Use (CHMP) to be granted marketing authorization in October 2022 and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …

Propyl alcohol

A colorless liquid made by oxidation of aliphatic hydrocarbons that is used as a solvent and chemical intermediate.
Approved
Matched Description: … A colorless liquid made by oxidation of aliphatic hydrocarbons that is used as a solvent and chemical …
Matched Categories: … Antiseptics and Disinfectants …

Necitumumab

Necitumumab is an intravenously administered recombinant monoclonal IgG1 antibody used in the treatment of non-small cell lung cancer (NSCLC) as an EGFR antagonist. It functions by binding to epidermal growth factor receptor (EGFR) and prevents binding of its ligands, a process that is involved in cell proliferation, metastasis, angiogenesis, and...
Approved
Investigational
Matched Description: … It functions by binding to epidermal growth factor receptor (EGFR) and prevents binding of its ligands ... , a process that is involved in cell proliferation, metastasis, angiogenesis, and malignant progression ... Necitumumab is approved for use in combination with cisplatin and gemcitabine as a first-line treatment …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Inulin

A starch found in the tubers and roots of many plants. Since it is hydrolyzable to fructose, it is classified as a fructosan. It has been used in physiologic investigation for determination of the rate of glomerular function.
Approved
Investigational
Nutraceutical
Matched Description: … A starch found in the tubers and roots of many plants. …
Matched Categories: … inulin and other polyfructosans ... Tests for Renal Function and Ureteral Injuries …

Gentian violet cation

A dye that is a mixture of violet rosanilinis with antibacterial, antifungal, and anthelmintic properties.
Approved
Matched Description: … A dye that is a mixture of violet rosanilinis with antibacterial, antifungal, and anthelmintic properties …
Matched Categories: … Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics …

Aprotinin

Aprotinin is a protein-based drug that is also known as bovine pancreatic trypsin inhibitor (BPTI). Since it demonstrates the capacity to slow fibrinolysis, it has been employed to reduce bleeding during complex surgery such as heart and liver surgery. For this use, it is typically administered by injection. The goal...
Approved
Investigational
Withdrawn
Matched Description: … to slow fibrinolysis, it has been employed to reduce bleeding during complex surgery such as heart and ... was subsequently to minimize end-organ damage resulting from hypotension due to blood loss in surgery and …
Matched Categories: … Blood and Blood Forming Organs ... Amino Acids, Peptides, and Proteins …

Tocainide

An antiarrhythmic agent which exerts a potential- and frequency-dependent block of sodium channels.
Approved
Matched Description: … An antiarrhythmic agent which exerts a potential- and frequency-dependent block of sodium channels. …

Trametinib

Trametinib is an orally bioavailable mitogen-activated extracellular signal-regulated kinase 1 (MEK1) and MEK2 inhibitor.[A258298,A258293] It was first approved by the FDA in May 2013 for the treatment of melanoma. It was later approved by Health Canada on July 18, 2013 and by the European Commission on June 30, 2014. Trametinib...
Approved
Matched Description: … Trametinib is an orally bioavailable mitogen-activated extracellular signal-regulated kinase 1 (MEK1) and ... [A258298] It was later approved by Health Canada on July 18, 2013 [L45588] and by the European Commission ... currently approved to treat a variety of cancers with BRAF mutations, such as non-small cell lung cancer and …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Afatinib

Afatinib is a 4-anilinoquinazoline tyrosine kinase inhibitor in the form of a dimaleate salt available as Boehringer Ingelheim's brand name Gilotrif [FDA Label]. For oral use, afatinib tablets are a first-line (initial) treatment for patients with metastatic non-small cell lung cancer (NSCLC) with common epidermal growth factor receptor (EGFR) mutations...
Approved
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Teplizumab

Teplizumab (teplizumab-mzwv) is a humanized IgG1 kappa CD3-directed monoclonal antibody used to delay the onset of type 1 diabetes (T1D).[A241480,A241045,A241475,L44091] T1D is an autoimmune condition in which T cell-mediated destruction of pancreatic β cells leads to loss of insulin production, impaired glycemic control, and reliance on exogenous insulin. Anti-CD3 therapy...
Approved
Investigational
Matched Description: … L44091] Fc-receptors can bind to the "tail-end" anti-CD3 antibodies in an antigen-non-specific manner and ... cell-mediated destruction of pancreatic β cells leads to loss of insulin production, impaired glycemic control, and ... mechanism of action of teplizumab has not been fully elucidated, it may involve partial agonistic signaling and …
Matched Categories: … Alimentary Tract and Metabolism ... Amino Acids, Peptides, and Proteins …
Displaying drugs 2251 - 2275 of 15114 in total